RO-7303509
RO-7303509 (MTBT1466A; RG-6315) is a human monoclonal antibody and TGFβ3 neutralizer. RO-7303509 targets the profibrotic mediator TGFβ3 to alleviate fibrosis. RO-7303509 can be administered via subcutaneous or intravenous routes and is used in research on systemic sclerosis. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
TGFβ3 |
Gene ID
Accession
P10600
Target
TGFB3
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
MTBT1466A; RG-6315
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
RO-7303509 Related Classifications
HY-P992453 Related Classifications
Powered by Bioz
Keywords
- RO-7303509
- MTBT1466A
- RG-6315
- RO7303509
- RO 7303509
- RG6315
- RG 6315
- RG-6315
- TGF-beta/Smad
- TGF-β Receptor
- Transforming growth factor beta
- Transforming growth factor beta receptors
- intravenous administration
- profibrotic mediator
- fibrosis
- systemic sclerosis
- TGFβ3
- human monoclonal antibody
- subcutaneous administration
- Inhibitor
- inhibitor
- inhibit